Fusion Board News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fusion board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fusion Board Today - Breaking & Trending Today
Share this article Share this article HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a member of the Company s Board of Directors. Dr. Bergstrom, who currently serves as executive vice president, head of research and development at Relay Therapeutics, Inc., a clinical stage precision medicines company, brings to the board more than 15 years of experience in the biopharmaceutical industry. Don s depth of precision oncology and industry experience will be invaluable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates, said Fusion Chief Executive Officer John Valliant, Ph.D. Additionally, his leadership and understanding of the oncology landscape will provide ....
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article HAMILTON, Ontario and BOSTON, Feb. 11, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company s Board of Directors. Dr. Lee, who currently serves as senior vice president, head of portfolio strategy at Blueprint Medicines Corporation, brings to the board 15 years of experience in the biopharmaceutical industry. She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical. Philina s depth of both precision oncology and radiopharmaceutical industry experience will be valuable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates, said Fusion Chief Executive Officer John Valliant, Ph.D. Addition ....